Table 1.
Design(s) | In Vivo Data | Viruses Tested for Neutralization 1 | Results 2 | Reference |
---|---|---|---|---|
Cyclized domain E peptides, truncated E2 core with additional domain E and HVR1 removed | Mouse | Homologous HCVpp: H77 Heterologous HCVpp: genotypes 1b, 4a |
Neutralized H77 in HCVpp assays | [77] |
E2 core with proline mutations in domain D or E, glycosylation of domain A, HVR1 removed | Mouse | Homologous HCVpp: H77 Heterologous HCVpp: genotypes 1b, 2a, 2i, 4a |
Increased neutralization of heterologous strains in HCVpp assays | [97] |
E2 core with truncated and designed HVR2, displayed on nanoparticles | Mouse | Homologous HCVpp: H77 Heterologous HCVpp: genotypes 1a, 2a, 5a |
Increased neutralization of H77 in HCVpp assays | [98] |
Cyclized and conjugated domain E peptide | Mouse | Homologous HCVcc: H77 Heterologous viruses: not tested |
Antibody isolated from mice non-neutralizing in HCVcc assays | [75] |
E2 core with eight cysteines mutated | Mouse | Homologous HCVpp: H77 Heterologous viruses: not tested |
No neutralization of H77 in HCVpp assays | [99] |
E1E2 ectodomains oligomerized with C4b-binding protein IMX313P | Mouse | Homologous virus: not tested Heterologous HCVpp: genotypes 1a, 1b, 2a, 2b, 3a, 4, 5, 6 |
Neutralized most strains in HCVpp assays | [100] |
E2 core with HVR1 and HVR2 removed, IgVR deglycosylated, and displayed on nanoparticles | Mouse | Homologous HCVpp: H77 Heterologous HCVpp: genotype 1b |
Increased neutralization of H77 in HCVpp assays | [101] |
E2 core fused to ferritin | Mouse | Homologous HCVcc: Con1 Heterologous HCVcc: genotypes 1a, 1b, 2a, 3a, 4a, 5a, 7a |
Increased neutralization of strains in HCVcc assays | [102] |
Synthetic consensus of E2 core from genotype 1 sequences | Guinea pig | Homologous HCVpp: NotC1 Heterologous HCVpp: genotypes 1a, 1b, 2a, 3 |
Increased neutralization of H77 in HCVpp assays | [103] |
E2 core with variable regions removed and seven cysteines mutated | Guinea pig | Homologous HCVpp: H77 Heterologous HCVcc: genotypes 2a, 3a, 5a |
Neutralized H77 HCVpp, limited neutralization of HCVcc | [104] |
Combination of two HVR1 peptides | Mouse | Homologous HCVpp: C47 Heterologous HCVpp: genotypes 1a, 1b, 2a, 3a, 4a, 5a, 6a |
Neutralized strains in HCVpp assays | [105] |
E2 with mutated N-glycan sites and HVR1 removed | Mouse | Homologous HCVcc: Jc1 Heterologous HCVcc: genotype 5a Heterologous HCVpp: genotype 1a |
Neutralized Jc1 HCVcc, H77 HCVpp | [106] |
E2 epitopes from domains B, D, and E, and HVR1 mimotope displayed on HBV-S VLPs | Mouse | Homologous virus: not tested Heterologous HCVpp and HCVcc: genotypes 1a, 1b, 2a |
Neutralized strains in HCVpp and HCVcc assays | [91] |
E2 epitopes from domains B-E displayed on HBV-S VLPs | Mouse | Homologous virus: not tested Heterologous HCVcc: genotypes 1a, 1b, 2a, 2b, 3a, 4a, 5a, 6a |
IgGs purified from sera neutralized some strains in HCVcc assays | [96] |
E1E2 ectodomains with C-terminal leucine zipper as scaffold, furin cleavage site | Mouse | Homologous HCVpp: H77 Heterologous viruses: not tested |
Neutralized H77 in HCVpp assays | [107] |
1 Homologous virus is listed by strain name; heterologous viruses are listed by genotype and subtype when known. 2 Summary of measured neutralization induced by design, or improvement in neutralization over non-designed control, if measured by the authors. Unless otherwise noted, results refer to serum neutralization.